Kimia T. Maleki

Huddinge, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in hantavirus-infected cells and correlates to severity in HFRS.

IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in hantavirus-infected cells and correlates to severity in HFRS.

Journal: PLoS pathogens

Published: January 11, 2025

Innate lymphoid cells are activated in HFRS, and their function can be modulated by hantavirus-induced type I interferons.

Innate lymphoid cells are activated in HFRS, and their function can be modulated by hantavirus-induced type I interferons.

Journal: PLoS pathogens

Published: April 25, 2024

Dynamic MAIT Cell Recovery after Severe COVID-19 Is Transient with Signs of Heterogeneous Functional Anomalies.

Dynamic MAIT Cell Recovery after Severe COVID-19 Is Transient with Signs of Heterogeneous Functional Anomalies.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: September 25, 2023

Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia.

Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia.

Journal: Respiratory research

Published: October 28, 2022

SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.

SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.

Journal: Cell reports

Published: October 12, 2021

High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19.

High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 21, 2021

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.

Journal: Clinical & translational immunology

Published: March 30, 2021

Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.

Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.

Journal: Clinical & translational immunology

Published: February 10, 2021

Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers.

Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers.

Journal: Scientific reports

Published: January 15, 2021

Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.

Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.

Journal: BMC infectious diseases

Published: December 26, 2020

Innate lymphoid cell composition associates with COVID-19 disease severity.

Innate lymphoid cell composition associates with COVID-19 disease severity.

Journal: Clinical & translational immunology

Published: October 12, 2020

MAIT cell activation and dynamics associated with COVID-19 disease severity.

MAIT cell activation and dynamics associated with COVID-19 disease severity.

Journal: Science immunology

Published: August 04, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026